
    
      Patients will be randomize to one of three arms: 4mg ondansetron pre-emergence, 8 mg
      ondansetron pre-emergence, or 4mg ondansetron pre-incision followed by 4mg ondansetron
      pre-emergence. Primary outcome will be incidence of PONV in the PACU prior to discharge.
    
  